Literature DB >> 1961352

Effect of high-dose dexamethasone in prednisone-resistant autoimmune thrombocytopenic purpura (ITP).

P Dubbeld1, C van der Heul, H F Hillen.   

Abstract

This study investigated whether high-dose dexamethasone pulse therapy could bring about a remission in adult chronic idiopathic thrombocytopenic purpura (ITP) patients who had not achieved a remission on the usual prednisone therapy. Newly diagnosed patients with ITP received the usual prednisone therapy, 1 mg/kg/day, for 3 weeks, after which period the dosage was tapered off. If after 6 weeks of treatment the platelets were less than 50 x 10(9)/l the prednisone therapy was considered a failure and 200 mg dexamethasone i.v. was given on 3 consecutive days. Six of the twenty-five patients with newly diagnosed ITP treated according to this protocol achieved a sufficient response with prednisone therapy. Nineteen patients were resistant to or relapsed during prednisone therapy and were treated with high-dose dexamethasone. Four of these nineteen patients showed a sufficient response. Three are still in remission. As no serious adverse effects were observed, high-dose dexamethasone therapy can be considered before splenectomy in prednisone- resistant ITP patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1961352

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  3 in total

1.  The mineralocorticoid effects of high dose hydrocortisone.

Authors:  B H Ramsahoye; S V Davies; N el-Gaylani; D Sandeman; M F Scanlon
Journal:  BMJ       Date:  1995-03-11

2.  High-dose dexamethasone as a replacement for traditional prednisone as the first-line treatment in children with previously untreated primary immune thrombocytopenia: a prospective, randomized single-center study.

Authors:  Jie Ma; Lingling Fu; Zhengping Chen; Hao Gu; Jingyao Ma; Runhui Wu
Journal:  Int J Hematol       Date:  2020-09-03       Impact factor: 2.490

3.  Multiple Myeloma Presenting with Autoimmune Autonomic Ganglionopathy.

Authors:  Yoshiki Nakae; Mizuki Hyuga; Yuta Terada; Wataru Kishimoto; Akiko Fukunaga; Sumie Tabata; Yoshitomo Maesako; Kenichi Komatsu; Osamu Higuchi; Toshinari Nakane; Nobuyoshi Arima
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.